The alarming increase in the risks of developing skin cancer has driven the search for more effective and accessible treatments. In response to this need, the Commercialization of Cuban Medical Services, S.A. offers a comprehensive oncological treatment program, backed by the experience and scientific excellence of professionals from the National Institute of Oncology and Radiobiology of Cuba.

This innovative treatment includes the use of HeberFERON®, a Cuban medication developed by the Center for Genetic Engineering and Biotechnology - with over 20 years of research and clinical trials - consisting of the synergistic combination of recombinant human Interferon alpha and gamma. It is especially indicated for the treatment of basal cell carcinomas in lesions of any size and location, even in high-risk areas such as the H zone of the face, or in locally advanced lesions that are difficult to treat due to proximity to the eyes or brain.

The benefits of this treatment are significant: it heals lesions and reduces tumor mass, induces a faster therapeutic response, extends treatment responses for up to five years, reduces the frequency of new lesion occurrence by eight times, avoids complex surgeries in sensitive areas such as the periocular zone, and improves the overall quality of life of the patient.

What distinguishes this program is its personalized approach. Each patient is evaluated by multidisciplinary teams of nationally and internationally certified specialists, who design a treatment plan tailored to the specific characteristics of their cancer. These teams are composed of internists, radiologists, pathologists, hematologists, surgeons, and clinical oncologists, among others.

To initiate this revolutionary treatment, interested parties can contact the Coordination and Processing Center of the Commercialization of Cuban Medical Services, S.A. via email at smc@smcsalud.cu, where they will be provided with detailed information about the medical program and its costs.

At a time when the fight against skin cancer is more urgent than ever, this new alternative offers hope and quality of life to those in need.

By: MSc. Dr. Patricia Alonso Galbán
Marketing and Communication Specialist, CSMC, S.A.